drugset / Trial / NCT04892498
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors
Timeline
- Start
- 2021-05-30
- Primary completion
- 2023-08
- Completion
- 2024-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM-CSF | Protein / enzyme biologic | 200 ug | — |
| Subject | IL-2 | Protein / enzyme biologic | 2e+06 iu | — |